ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Aspira Womans Health Inc

Aspira Womans Health Inc (AWH)

0.082
0.00
(0.00%)
Closed 27 April 6:00AM
0.00
0.00
(0.00%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.082
Bid
0.0398
Offer
0.042
Volume
-
0.00 Day's Range 0.00
0.077 52 Week Range 3.45
Market Cap
Previous Close
0.082
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
4,902,556
Shares Outstanding
29,764,248
Dividend Yield
-
PE Ratio
-0.14
Earnings Per Share (EPS)
-0.56
Revenue
9.15M
Net Profit
-16.69M

About Aspira Womans Health Inc

Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-c... Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Show more

Sector
In Vitro,in Vivo Diagnostics
Industry
In Vitro,in Vivo Diagnostics
Headquarters
Wilmington, Delaware, USA
Founded
-
Aspira Womans Health Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker AWH. The last closing price for Aspira Womans Health was US$0.08. Over the last year, Aspira Womans Health shares have traded in a share price range of US$ 0.077 to US$ 3.45.

Aspira Womans Health currently has 29,764,248 shares in issue. The market capitalisation of Aspira Womans Health is US$2.44 million. Aspira Womans Health has a price to earnings ratio (PE ratio) of -0.14.

AWH Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.0820.0820.08200CS
4-0.0269-24.70156106520.10890.10990.0777999130.0921492CS
12-0.323-79.75308641980.4050.420.07749025560.16224926CS
26-0.918-91.811.01550.07723547200.17259544CS
52-3.248-97.53753753753.333.450.07712155670.22056378CS
156-11.678-99.302721088411.7616.50.0775852542.56440573CS
260-62.018-99.867954911462.1158.10.07765003727.35293897CS

AWH - Frequently Asked Questions (FAQ)

What is the current Aspira Womans Health share price?
The current share price of Aspira Womans Health is US$ 0.082
How many Aspira Womans Health shares are in issue?
Aspira Womans Health has 29,764,248 shares in issue
What is the market cap of Aspira Womans Health?
The market capitalisation of Aspira Womans Health is USD 2.44M
What is the 1 year trading range for Aspira Womans Health share price?
Aspira Womans Health has traded in the range of US$ 0.077 to US$ 3.45 during the past year
What is the PE ratio of Aspira Womans Health?
The price to earnings ratio of Aspira Womans Health is -0.14
What is the cash to sales ratio of Aspira Womans Health?
The cash to sales ratio of Aspira Womans Health is 0.26
What is the reporting currency for Aspira Womans Health?
Aspira Womans Health reports financial results in USD
What is the latest annual turnover for Aspira Womans Health?
The latest annual turnover of Aspira Womans Health is USD 9.15M
What is the latest annual profit for Aspira Womans Health?
The latest annual profit of Aspira Womans Health is USD -16.69M
What is the registered address of Aspira Womans Health?
The registered address for Aspira Womans Health is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Aspira Womans Health website address?
The website address for Aspira Womans Health is www.aspirawh.com
Which industry sector does Aspira Womans Health operate in?
Aspira Womans Health operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WWWW International Inc
US$ 0.395
(167.62%)
223.58M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M
GREEGreenidge Generation Holdings Inc
US$ 1.3197
(53.92%)
5.84M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.28
(44.30%)
38.04M
CGTLCreative Global Technology Holdings Ltd
US$ 1.5197
(-75.09%)
3.88M
TOIIWOncology Institute Inc
US$ 0.1015
(-40.22%)
156.14k
COEPCoeptis Therapeutics Holdings Inc
US$ 7.70
(-38.25%)
716.99k
INTSIntesity Therapeutics Inc
US$ 0.56
(-37.78%)
3.21M
SMMTSummit Therapeutics Inc
US$ 23.47
(-36.05%)
24.67M
GNLNGreenlane Holdings Inc
US$ 0.012699
(-15.34%)
355.22M
AGMHAGM Group Holdings Inc
US$ 0.0477
(22.31%)
340.91M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.455
(19.62%)
266.95M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M

AWH Discussion

View Posts
whytestocks whytestocks 5 years ago
BREAKING NEWS: $AWH What Are The Best Penny Stocks On Robinhood To Buy Right Now? 4 To Watch

Are These Robinhood Penny Stocks On Your Watch List Right Now? One of the fastest-growing platforms for trading penny stocks in 2020 is Robinhood. Like it or hate it, Robinhood has scaled up to 13 million users, growing even more popular. Despite the multiple shortcomings of the...

Find out more AWH - What Are The Best Penny Stocks On Robinhood To Buy Right Now? 4 To Watch
๐Ÿ‘๏ธ0
whytestocks whytestocks 5 years ago
BREAKING NEWS: $AWH Are These Epicenter Penny Stocks To Buy Amid Reopening Efforts?

Reopening Penny Stocks To Buy Or Sell Right Now Whether you call them reopening stocks, epicenter stocks , or just penny stocks , certain businesses could benefit from things “getting back to normal.” But that will eventually figure itself out as the year progresses and we see ...

Read the whole news AWH - Are These Epicenter Penny Stocks To Buy Amid Reopening Efforts?
๐Ÿ‘๏ธ0
DTGoody DTGoody 5 years ago
AWH Making a nice move in afterhours! Can't wait for this to really take off soon!
๐Ÿ‘๏ธ0
DTGoody DTGoody 5 years ago
Vermillion, Inc. Announces Rebranding and Company Name Change to Aspira Womenโ€™s Health Inc.
June 11, 2020 08:31 ET

AUSTIN, Texas, June 11, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based womenโ€™s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the companyโ€™s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change to Aspira Womenโ€™s Health Inc effective today, June 11, 2020. The companyโ€™s common stock will trade on the Nasdaq Stock Market under the new ticker symbol โ€œAWHโ€ effective June 12, 2020.
Over the past 12 months, Aspira Womenโ€™s Health has established its foundation as the market leader for ovarian cancer risk assessment while beginning product development to expand into large benign gynecologic disease markets. The companyโ€™s goal is to serve the large pelvic mass market, 20 million women in the US, and 200 million women worldwide, with proprietary products throughout the entire patient lifecycle. The Company has experienced an increase in its US customer base of ordering physicians from 1,400 in 2018 to 2,700 for 2019, a 56% increase. The Company has 85 filed and 40 pending patents. This growth reflects the trust and adoption of OVA1 ® plus coupled with real-time innovations such as the addition of germline genetic testing and ethnic disparity solutions. Portfolio expansion development includes: pelvic mass monitoring, endometriosis, and high-risk ovarian cancer screening for those genetically predisposed.

โ€œToday marks a significant milestone for our company,โ€ said Valerie Palmieri, President, and Chief Executive Officer of Aspira Womenโ€™s Health. โ€œOur new company name captures the soul of our companyโ€™s mission and vision. With this name change, we are solidifying our commitment to solving big womenโ€™s health issues such as endometriosis and ovarian cancer detection for all ethnicities, stages, and ages. Through our data-driven approach, we aim to deliver solutions that help women โ€œAspireโ€ to take control of their gynecologic health and โ€œEmpowerโ€ providers to deliver optimal care.โ€

As part of the name change, the company has a new stock ticker symbol (AWH) and a new CUSIP (04537Y109) and has relaunched its website as www.aspirawh.com , and rolled out a new company logo and associated icon pictorially connecting the dots for gynecologic womenโ€™s health.

The company has used the name, โ€œVermillion Inc.โ€ for more than 13 years, during which it has been known for developing FDA cleared ovarian cancer risk assessment tests OVA1 ® and OVERA ® . The name change will not affect the quality of products or services offered by the company.

The Company anticipates holding a conference call later this month to discuss the rebranding and expanded portfolio. Details of the call will follow on a later date.

About Aspira Womenโ€™s Health Inc.
Aspira Womenโ€™s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming womenโ€™s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 ® plus combines our FDA-cleared products OVA1 ® and OVERA ® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX SM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Visit our website for more information about our products at www.aspirawh.com .

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com
๐Ÿ‘๏ธ0
DTGoody DTGoody 5 years ago
$VRML Vermillion Set to Join Russell 3000® Index
June 09, 2020 16:34 ET
AUSTIN, Texas, June 09, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc.

(Nasdaq: VRML), a bioanalytical-based womenโ€™s health company focused on gynecologic disease, today announced that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020, according to a preliminary list of additions posted on June 5, 2020.
Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 8, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

โ€œWe are thrilled to join the Russell 3000 ® , which we believe will attract broader interest in Vermillion from institutional investors and investment funds,โ€ said Valerie Palmieri, Chief Executive Officer of Vermillion, Inc. โ€œWe have made tremendous progress this year, both operationally and in year-over-year top line growth, even in the face of the challenges from the COVID-19 pandemic. We look forward to an easing of restrictions around the globe and a return to a more normal environment.โ€

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russellโ€™s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the โ€œRussell Reconstitutionโ€ section on the FTSE Russell website .

About FTSE Russell

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com

About Vermillion Inc.

Vermillion, Inc. is transforming womenโ€™s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 ® plus combines our FDA-cleared products OVA1 ® and OVERA ® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans. Visit our website for more information about our products at www.vermillion.com .

Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995 including statements regarding the anticipated addition of Vermillion common stock to the Russell 3000 Index and effects thereof. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as โ€œmay,โ€ โ€œexpects,โ€ โ€œintends,โ€ โ€œanticipates,โ€ โ€œbelieves,โ€ โ€œestimates,โ€ โ€œplans,โ€ โ€œseeks,โ€ โ€œcould,โ€ โ€œshould,โ€ โ€œcontinue,โ€ โ€œwill,โ€ โ€œpotential,โ€ โ€œprojectsโ€ and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties inherent in Vermillionโ€™s business, including those described in the section entitled โ€œRisk Factorsโ€ in Vermillionโ€™s Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by the section entitled โ€œRisk Factorsโ€ in Vermillionโ€™s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The events and circumstances reflected in Vermillionโ€™s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.
?
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@LifeSciAdvisors.com
๐Ÿ‘๏ธ0
Sam Dan Sam Dan 9 years ago
AWH now known as KNR Trading started but now halted
๐Ÿ‘๏ธ0
Sam Dan Sam Dan 9 years ago
Also watch for results from NEMASKA

ABR holdins abuts NEMASKA holdings. Positive news from them would be a major plus for ABR.
NEMASKA LITHIUM BEGINS A TARGETED DEFINITION DRILLING CAMPAIGN ON THE WHABOUCHI PROJECT WITH THE OBJECTIVE TO INCREASE THE EXISTING LITHIUM RESOURCE AND EXTEND THE MINE LIFE

Nemaska Lithium Inc. has begun a $1.5-million budget definition drilling campaign for the Whabouchi project in the Eeyou Istchee James Bay region. The main goals of this program are to convert the existing in-pit inferred resource into measured and indicated, to add near surface resources in the east zone of the pit design as well as confirm continuity of further resources at depth below the 200 m level.

"Assuming we achieve our goals, this drill program will enable us to increase our open pit mine life, reduce the stripping ratio and lower the production cost of concentrate," said Guy Bourassa, President and CEO of Nemaska Lithium. "In addition to having a clearer idea of the full potential of the lithium resource at Whabouchi, this drilling program enables management as well as shareholders to fully value our project."

The drilling program, involving an anticipated 44 drill holes spread over 13,700 m, is expected to be completed in September 2016. The feasibility study titled: NI 43-101 Technical Report Feasibility Study Update on the Whabouchi Lithium Deposit and Hydromet Plant (Revised), covers mineral resources totalling 27.9 Mt with an average grade of 1.57% Li2O in the measured and indicated categories and 4.69 Mt with an average grade of 1.51% Li2O of inferred resources in an optimized pit with a 0.43% Li2O cut-off grade. The three main objectives of the drilling campaign are:

1. The potential conversion of 4.69 Mt of inferred resources, inside pit design, to indicated resources, representing a potential upgrade between 15 and 25% of resources that could be converted to reserves (that is, measured and indicated resources). This phase involves 5,900 m covering 22 drill holes. (See Fig. 1)

2. The second objective is to increase the level of confidence of mineral resources between 0 m and 200 m vertical from the surface. This phase would potentially make it possible to fill the East section of the longitudinal zone, which does not include any resources at the moment. A total of 17 drill holes over a 5,100 m surface area are expected to be drilled in order to meet this objective. This phase is expected to result in a potential increase block model volume between 20 and 35%. (See Fig. 2)

3. Finally, the drilling program aims to confirm the continuity of the longitudinal zone of mineral resources down to 500 m vertical depth, below surface. Five drill holes for a total of 2,700 m are expected to be drilled in order to meet this objective. This could potentially allow an increase between 30 and 45% in the longitudinal zone covered by the mineral resource model. (see Fig. 3)

The drilling campaign is supervised by Jean-Philippe Paiement, M.Sc. P. Geo, at SGS Canada Inc. Forage Rouiller has been chosen to carry out drilling. Samples shall be prepared by the SGS Canada Inc. laboratory in Quebec City and shall be analyzed by the SGS Canada Inc. accredited laboratory in Vancouver.

A QAQC program involving blank samples, standard samples and field duplicates shall be established during sampling. The work shall be carried out in accordance with CIM's mining exploration guidelines.

The technical parts of this press release were prepared by Jean-Philippe Paiement, M.Sc. P. Geo, at SGS Canada Inc., qualified person under Regulation NI 43-10
๐Ÿ‘๏ธ0
Sam Dan Sam Dan 9 years ago
Could be positive
ASHBURTON TO MOBILIZE DRILL AT BUCKINGHAM GRAPHITE PROPERTY, QUEBEC

Ashburton Ventures Inc. has received all drilling and access permits, and approvals have been received, and the company is mobilizing a crew to commence a second-phase drill program on its Buckingham graphite property located in southwestern Quebec. The program will expand on previous drilling completed in late 2015. The initial drilling program will consist of up to 1,000 metres of core drilling and will be aimed at further testing the 1.1-kilometre-long, northeast-oriented geophysical conductor, located on the southern part of the property.

President and chief executive officer Michael England stated, "We are excited to report commencing this follow-up drill program to last winter's successful campaign at Buckingham which encountered significant intercepts from five out of five holes drilled."

Following the success of the last drill program, Ashburton further announces it has engaged Inlandsis Consultants of Montreal, Que., to write a National Instrument 43-101 report on the Buckingham graphite project.

The Buckingham graphite property consists of 18 claims in ranges VIII and IX, Buckingham township, Quebec, which cover an area of 1,082 hectares. Exploration on the southern part of the claim group has yielded assay results as high as 21.6 per cent Cg (graphitic carbon) over 14.5 metres from channel samples and purity results up to 96.1 per cent Ct (total carbon) from large-flake fractions (see Cavan press release dated July 17, 2014, and May 28, 2015). A first-phase drill program returned assays of 112 metres of 4.07 per cent (see press release dated Feb. 11, 2016) as well as 16 m of 11.09 per cent Cg and 88 m of 3.29 per cent Cg (see press release dated June 23, 2016).

The technical content of this news release was approved by Dr. Michel Boily, PGeo, director of Ashburton and a qualified person as defined by National Instrument 43-101.
๐Ÿ‘๏ธ0
Sam Dan Sam Dan 9 years ago
Progress- whatch for assays in 4-6 weeks
๐Ÿ‘๏ธ0
Sam Dan Sam Dan 10 years ago
New project and reverse split of shares

ARROWHEAD GOLD TO ACQUIRE NUVO ENERGY GRID INC.
Arrowhead Gold Corp. has signed a letter of intent to acquire 100 per cent of the outstanding shares of Nuvo Energy Grid Inc., a private company, with its headquarters in Toronto, Ont.

Pursuant to the LOI, Arrowhead will acquire all shares of Nuvo from the Nuvo shareholders in exchange for 13.25 million post consolidated common shares of Arrowhead. Nuvo has sufficient working capital to develop its business plan.

AWH proposes to reduce the number of Common Shares of the Company, as management believes it is in the Company's best interest to consolidate the shares to increase the Company's share price and conceivably improve trading liquidity. Many brokerage houses and institutional investors have policies which either, incline to exclude individual brokers from recommending low-priced shares to their customers, or prohibit them from investing in low-priced shares. Upon completion of a proposed 1:6 consolidation, AWH's current issued capital of 20,940,494 common shares would become 3,490,080 common shares. The proposed consolidation is subject to Shareholder and Regulatory approval.

Management of AWH are required to enter into a voting support agreement pursuant to which they will vote their shares of AWH in support of the transactions set out in the LOI.

Nuvo will nominate candidates for election to AWH's Board of Directors.

AWH will obtain all applicable regulatory and shareholder approvals. All steps necessary will be taken to change the name of Arrowhead Gold Corp. to Nuvo Energy Grid Inc.

Nuvo Energy Grid Inc.

Nuvo is a Private Canadian Company based out of Toronto, Ontario. The company is focused on acquiring companies in the Energy Efficiency and Technology sectors. Driven by the rising cost of electricity across North America the energy efficiency market is enjoying double digit annual growth rates and according to Pike Research, the "Global Energy Efficiency" market is valued at $300 Billion as an annual industry.

Much in the same way that smartphones have come to enhance the way we communicate, the world of connected energy technology is all about enhancing the way your living and work space communicates. One of the best examples right now is the Nest Thermostat. Nest Labs was created to build products that change how we use regular energy technology, with an immediate focus on efficiency, safety, and ease of use. In January 2014, Google Inc. entered into an agreement to acquire 100% of Nest Labs for a total purchase price of $3.2 billion.

Paul Ghezzi, CEO of Nuvo says, "We are entering a period of convergence between energy and the 'Internet of Things'. Nuvo is positioned to take advantage of this rapidly growing market sector through the acquisition and/or development of intelligent energy technology, data mining, energy demand, integration and energy services management. Additional technology targets include smart plugs, smart controls and smart battery storage."

Nuvo has targeted a number of private companies in the smart and" internet of things" sector and energy service companies with positive EBITDA, that are potential accretive acquisitions in the first half of 2016.

Board of Directors and Management

Paul Ghezzi, CPA, CA, CEO

Mr. Ghezzi has been a leader in the renewable energy sector since 2008. He created Canada's first Solar Energy Income Fund by securitizing cash flows from long-term Power Purchase Agreements. Most recently he has been the President of EHT, a publically traded company on the TSX-V, and has helped EHT acquire one of the largest solar energy commercial rooftop portfolios in North America. Mr. Ghezzi has more than 20 years of corporate finance and M&A experience with a special focus on renewable energy development, renewable energy financing, solar project financing and distributed generation. Mr. Ghezzi has developed more than 100 Megawatts of renewable energy projects globally and has experience in Feed in Tariff programs and Net-Metered markets.

Claudio Del Vasto, CPA, CA, CFO

Mr. Del Vasto is a former Director of Structured Finance at Bombardier with extensive global experience in arranging large scale complex commercial transactions. During his tenure, Mr. Del Vasto has participated in deal closings valued at more than $3 Billion that involved equity, mezzanine debt, senior debt and capital markets funding. Prior to his career in industry, he was a public accountant managing tax, accounting and assurance services.

Andrew Bowerbank, Director

Mr. Bowerbank is Director of Sustainable Building Services at EllisDon Corporation. Mr. Bowerbank is the former Executive Director/CEO of the World Green Building Council (2007-10) representing over 60 member nations. During his tenure with the WorldGBC, he was proud to act as the member representative at the United Nations Environmental Programme. In addition to his current work as Director, Sustainable Building Services at EllisDon, Mr. Bowerbank is a Council member at the Federation of Canadian Municipalities in Ottawa, a Board member at CDML, and a member of the BRE Global Standing Panel of Experts (UK).

Jim MacDougall, Director

Mr. MacDougall is the Managing Director of Compass Consulting and a veteran of the Ontario electricity industry. He has had in-depth experience in the design, development and implementation of renewable energy procurement in Ontario, and offers clients expertise and insight on IESO and LDC programs. Mr. MacDougall's career spans the Ontario electricity sector and covers a broad mix of large scale utility projects and commercial scale projects both in the demand and supply value chain.




๐Ÿ‘๏ธ0
Sam Dan Sam Dan 10 years ago
Hope they eventually find a viable project.Nothing we can do but wait and wait

Mr. Steve Smith reports

ARROWHEAD GOLD TERMINATES LOI TO ACQUIRE BIO THERAPEUTIC MOLECULES INC.

Arrowhead Gold Corp., as per its news release of March 15, 2015, is terminating the letter of intent to acquire 100 per cent of the outstanding shares of Bio Therapeutic Molecules Inc. (BTMI).

BTMI was unsuccessful in its initial application to produce marijuana for medical purposes, under the marihuana for medical purposes regulations (MMPR), which came into force in June, 2013.

Arrowhead is currently exploring other opportunities in technology and other markets.



๐Ÿ‘๏ธ0
Sam Dan Sam Dan 10 years ago
2 months later another update .
Hope they can satisfy the necessary funding requirements.

"Arrowhead Gold Corp (2) (C:AWH)
Shares Issued 15,471,761
Last Close 6/17/2015 $0.025
Thursday June 18 2015 - News Release

Mr. Steve Smith reports

ARROWHEAD GOLD TO SIGN DEFINITIVE AGREEMENT TO ACQUIRE BIO THERAPEUTIC MOLECULES INC.

As per its news release of March 15, 2015, Arrowhead Gold Corp. is moving forward with a definitive agreement to acquire 100 per cent of the outstanding shares of Bio Therapeutic Molecules Inc. (BTMI), a private company, with its headquarters in Guelph, Ont.

Pursuant to the agreement, Arrowhead will acquire all shares of BTMI from the BTMI shareholders in exchange for 41.5 million common shares of Arrowhead.

Closing is contingent upon completion of a financing and to have a minimum $2.0 million on deposit after closing. Management of AWH are required to enter into a voting support agreement pursuant to which they will vote their shares of AWH in support of the transactions set out in the LOI.

BTMI will nominate candidates for election to AWH's Board of Directors.

AWH will obtain all applicable regulatory and shareholder approvals.

Bio Therapeutic Molecules Inc.

BTMI has a multi-disciplinary scientific team of principals and advisors who are experts in horticultural science, including metabolism, biochemistry, physiology, breeding and production, as well as the pharmaceutical industry, including discovery, development, manufacturing and marketing of drugs.

BTMI has developed a two-platform business model:

- Generating immediate cash flow (with growth potential) in Product Development and Research Management (PDRM) services. PDRM services will include: Opportunity Assessment (Market Analysis, Due Diligence); CMC (Chemistry, Manufacturing and Controls) Management; Project Management; and, Clinical and Pre-Clinical Toxicology.

Cash flow from these services will be used to develop an equity stake in a portfolio of "Active Pharmaceutical Ingredient" (API) and drug products with long-term value potential.

- BTMI has submitted an application to Health Canada to become a Licensed Producer of Medical Marihuana. Direct sale of dried marihuana against current regulation will support near term growth, and discovery activities with respect to phyto/bio-active molecules will be pursued to establish a pipeline of potential products for longer term growth.

Cash flow from sale of medicinal marihuana will be used to auto finance R&D into Cannabis-based pharmaceutical products."




๐Ÿ‘๏ธ0
Sam Dan Sam Dan 10 years ago
A NEW LIFE FOR AWH
Maybe marijuana will make us feel better!
Basically a vehicle for the private company to go public.
Hang on .
"ARROWHEAD GOLD TO ACQUIRE BIO THERAPEUTIC MOLECULES INC.

Arrowhead Gold Corp. has signed a letter of intent to acquire 100 per cent of the outstanding shares of Bio Therapeutic Molecules Inc., a private company, with its headquarters in Guelph, Ont.

Pursuant to the LOI, Arrowhead will acquire all shares of BTMI from the BTMI shareholders in exchange for 41.5 million common shares of Arrowhead, providing both AWH and BTMI are satisfied with due diligence to be conducted over a 60 day due diligence period.

AWH will be required to complete a financing and to have a minimum $2.0 million on deposit after closing. Management of AWH are required to enter into a voting support agreement pursuant to which they will vote their shares of AWH in support of the transactions set out in the LOI.

BTMI will nominate candidates for election to AWH's Board of Directors.

AWH will obtain all applicable regulatory and shareholder approvals.

Following the closing of the acquisition of BTMI: i. Funds will be utilized to implement the Corporation's business plan; and, ii. All steps necessary will be taken to change the name of Arrowhead Gold Corp. to Bio Therapeutic Molecules Inc.

Bio Therapeutic Molecules Inc.

BTMI will focus on the identification, investigation and development of plant-derived therapeutics in the natural health and pharmaceutical space for the treatment of chronic ailments and unmet medical needs. Plant lines will be established as pharma-grade Active Pharmaceutical Ingredients (APIs) and derived pharmaceutical products will be identified through discovery and partnership pursuits. One of the key pillars for success will be the establishment of a facility for the production of pharma-grade APIs that meet all regulatory, quality and safety expectations for their intended use.

BTMI will use cannabis as the model system to establish requirements to grow medicinal APIs that meet regulatory, quality and safety expectations of the pharmaceutical industry. To support this strategy BTMI has submitted an application to Health Canada to become a Licensed Producer of Medical Marihuana. Also, BTMI is pursuing the development of facilities and approvals for temporary space to begin research and development activities immediately. Direct sale of dried marihuana against current regulation will support near term growth, and discovery activities with respect to phyto/bio-active molecules will be pursued to establish a pipeline of potential products for longer term growth.

BTMI is located in the Ontario Technology Triangle. Its proximity to the University of Guelph, generally considered as Canada's leading Plant Biology/Biotechnology university, to McMaster University, whose Faculty of Health Sciences is a leader in biomedical and health care research, to Waterloo University, whose School of Pharmacy recently introduced a Doctor of Pharmacy (PharmD) degree, and to Niagara College, which plays a preeminent role in training personnel for the Horticultural Industry, positions the Company to attract additional highly qualified, experienced and entry-level employees.

BTMI has a multi-disciplinary scientific team of principals and advisors who are experts in horticultural science, including metabolism, biochemistry, physiology, breeding and production, as well as the pharmaceutical industry, including discovery, development, manufacturing and marketing of drugs.

Board of Directors and Management

(Additional key members of the BTMI team will be disclosed following completion of the transaction).

Dr. Gene Shelp - Chief Executive Officer, Chairman of Board and Director, Co-founder. President & CEO, Director and Co-founder of ENPAR Technologies Inc. PhD Environmental Geochemistry, University of Guelph Dr. Barry Shelp - Vice President Research and Development, Director, Co- founder. Full Professor, Department of Plant Agriculture, University of Guelph PhD Plant Physiology and Biochemistry, Queen's University Mr. John Suk - Director 35+ Years in Canadian Pharmaceutical Industry President & CEO of Altana Pharma from 1997- 2011 Hons BSc Biological Sciences, Brock University Mr. Louis Schenck - Director Owner and operator of Schenck Farms and Greenhouses (St. Catharines, Ontario) MBA Schulich School of Business, York University BA Economics, University of Western Ontario Dr. Adel Zarei - Master Grower Post-doctoral Fellow and Research Associate, Department of Plant Agriculture, University of Guelph PhD in Plant Phytopathology, Leiden University, The Netherlands Mr. Kurt Almquist - Medical Science Liaison Medical Scientific Liaison, MediResource Company, Toronto Hons BSc Life Sciences, Queen's University

Scientific Advisory Team

(Consists of key participants in pharmaceutical, plant science and industry sectors)

Dr. Susan P. C. Cole - Pharmacology and Cancer Therapeutics Full Professor, Department of Pathology & Molecular Medicine, Queen's University Dr. David J. Wolyn - Plant Breeding Full Professor, Department of Plant Agriculture, University of Guelph Mr. William N. MacDonald - Indoor Plant Production Professor of Horticulture, Niagara College in Niagara-on-the-Lake Dr. Luc C Duchesne - Industrial Research and Commercialization President & CEO, GSN Dreamworks Inc.


๐Ÿ‘๏ธ0
RowingDude RowingDude 11 years ago
Good morning Arrowhead Gold Corp. (TSX:AWH)
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 13 years ago
Scoreboard for the week: -20.00%
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 13 years ago
For the week: +16.00% (chart)

......
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 13 years ago
Arrowhead Gold Corp Closes Private Placement

(via company e-mail alert)

VANCOUVER, Canada December 13, 2011 โ€“ Arrowhead Gold Corp. (the โ€œCompanyโ€) (TSXV: AWH)is pleased to announce it has closed its non- brokered private placement for gross proceeds totalling $500,000. These finances were raised by the company issuing up to 5 million units at a price of 10 cents per unit, each unit consisting of one common share and one-half of one share purchase warrant. Each whole warrant will entitle the holder, on exercise, to purchase one common share for a period of two years, at a price of 15 cents.

A cash commission of 10 per cent totalling $27,050 was paid by the Company, on a portion of the gross proceeds of the offering, to the agents as consideration for arranging the offering. The Company also issued agentsโ€™ warrants, which entitle the agents to purchase up to 135,250 common shares of the Company at a price of 15 cents per share until December 12, 2013.

The securities issued pursuant to the offering, and any common shares to be issued upon the exercise of the warrants and agentsโ€™ warrants, are subject to a hold period expiring April 13, 2012.

On Behalf of the Board of Arrowhead Gold Corp.,

โ€œSteve Smithโ€
President

๐Ÿ‘๏ธ0
Pro-Life Pro-Life 13 years ago
Another new 52 week low... yikes!
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Name change... in case you were wondering...
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Otish Samples up to 1940.0 Grams Per Tonne at Purini Project, Guyana

http://www.otishenergyinc.com/newsroom/index.html

VANCOUVER, Canada, July 28 2011 โ€“ Otish Energy Inc. (the โ€œCompanyโ€) (TSXV: OEI)is pleased to announce rock sample assay results from its wholly owned Puruni Gold Project in the Mazaruni Mining District No. 3, Guyana.

Sample PRX-01 returned 1940.0 grams per tonne gold (gpt Au) or 56.8 ounces per ton gold (opt Au). Sample PRX-02 returned 503.8 gpt Au (14.71 opt Au). Sample PRX-03 returned 791.3 gpt Au (23.28 opt Au). The samples are selective grabs taken from quartz boulders recently excavated from Zone A on the Puruni Property. Zone A is marked by a strong induced polarization anomaly and a coincident gold-in-soil geochemical anomaly.

The sampling was completed by the Otish Gold (Guyana) field crew under the supervision of Martin Zambrano, Senior Geologist. All analytical work was completed at Acme Analytical Laboratories Ltd. (โ€œAcmeโ€) in Vancouver, B.C. Acme is accredited under ISO 9001. The samples were bagged on site and then delivered to Acmeโ€™s facility in Georgetown, Guyana where they were prepared by crushing one kilogram to 80% passing 10 mesh and then pulverizing a 250-gram pulp subsample to 85% passing 200 mesh. The pulps were shipped to Vancouver and initially analyzed for gold by 30g fire assay ICP-MS technique. All three samples were above the detection limit of this technique and accordingly were re-assayed using 30g fire assay gravimetric technique.

โ€œThese sample results and the recent induced polarization results suggest the possibility of a gold-bearing quartz vein structure. Drilling is required to confirm the existence of this structureโ€, states Martin Zambrano, Senior Geologist. Mark Fekete, PGeo., a designated qualified person as defined in Section 1.2 in and for the purposes of National Instrument 43-101, has reviewed the technical content of this press release.

On Behalf of the Board of Otish Energy Inc.

Steve Smith,

President

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The Company disclaims any intention or obligation to revise or update such statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
For the week: -3.45%... watching vigilantly.
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Down for the week: -3.33%... buy territory?
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
-12.24% is the scorecard for the week...
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Otish Energy Announces Increase to Private Placement

(delivered through e-mail)

VANCOUVER, BRITISH COLUMBIA--(March 11, 2011) - Otish Energy Inc. (the "Company") (TSX VENTURE:OEI) - Steve Smith, the President of the Company announces that due to increased demand, the Company has agreed to increase the private placement announced on February 22, 2011 from $500,000 to $638,500. These funds will be raised by the Company issuing up to 3,167,500 million units at a price of $0.20 per unit, each unit consisting of one common share and one-half of one share purchase warrant. Each whole warrant will entitle the holder, on exercise, to purchase one common share for a period of one year, at a price of $0.25.

Finder's fees may be payable on a portion of the private placement, in accordance with the policies of the TSX Venture Exchange.

The private placement is subject to the approval of the TSX Venture Exchange.

The net proceeds of the private placement will be used to further exploration on the Company's properties and for working capital purposes.

On Behalf of the Board, Otish Energy Inc.

Steve Smith, President

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The Company disclaims any intention or obligation to revise or update such statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact

Otish Energy Inc.
Steve Smith, President
(604) 642-0115
(604) 642-0116 (FAX)
steve.smith@telus.net

Follow Otish Energy On:


Facebook: http://www.facebook.com/pages/Otish-Energy-Inc/150936298261237
Twitter: http://twitter.com/OtishEnergy
YouTube: http://www.youtube.com/user/OtishEnergy
Flickr: http://www.flickr.com/photos/otishenergy
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Nothing but strength that last few days.
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
My friends, for the week: +5%!!!
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
A warm welcome to mercurialmike for the mod/dd team.
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Correcting now and looking to add as much as possible.
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Otish Energy Options Three Gold Properties in Guyana, SA

http://finance.yahoo.com/news/Otish-Energy-Options-Three-ccn-1350441702.html?x=0&.v=1

Press Release Source: Otish Energy Inc. On Friday December 17, 2010, 9:30 am EST

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 17, 2010) - Otish Energy Inc. (the "Company") (TSX VENTURE:OEI - News) is pleased to announce it has signed letters of intent with Mr. Kennard Gobin of East Coast Demerara, Guyana, SA to acquire all of the hard rock mining rights (the "Rights") for the Guyana Geology and Mines Commission Mining Permit No. 187/2010, Guyana Geology and Mines Commission Mining Prospecting Permit PPMS/626/2010 and Guyana Geology and Mines Commission Mining Prospecting Permit PPMS/627/2010 in the Cuyuni Mining District #4, Guyana SA.

The consideration payable by the Company for the purchase of the Rights will be US$10,000 payable in cash and 600,000 common shares in the capital stock of the Company which shares will subject to the usual 4 month restricted period required by the TSX Venture Exchange and applicable securities legislation.

The purchase of the Rights is subject to due diligence by the Company and the completion of formal documentation.

The Company is also pleased to announce that the assignment agreement with Trevor Taylor of Ajax, Ont., (previously announced in Stockwatch June 25, 2010) whereas Mr. Taylor agrees to transfer to the company his exclusive and sole right title and interest in the contiguous land block comprising six medium-scale prospecting permits, comprising approximately 6,900 acres, located in Puruni, Mazaruni mining district No. 3, Guyana is near completion. The Company anticipates commencing a detailed exploration program on the Purini project in early January 2011.

๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
Otish Energy Options Kaburi Gold Project in Guyana, SA

http://finance.yahoo.com/news/Otish-Energy-Options-Kaburi-ccn-199169011.html?x=0&.v=1

Press Release Source: Otish Energy Inc. On Friday December 17, 2010, 10:41 am EST

VANCOUVER, BRITISH COLUMBIA--(Dec. 17, 2010) - Otish Energy Inc. (the "Company") (TSX VENTURE:OEI) pleased to announce it has signed a letter of intent with Misters Clinton and Henry Alphonso, of Georgetown Guyana, SA, whereby the Company will acquire all of the hardrock mining rights (the "Rights") in the Guyana Geology and Mines Commission Large Scale Prospecting Licence No. 01/2009 in the Kaburi Area, Mazaruni, Guyana SA.

The consideration payable by the Company for the purchase of the Rights will be one hundred and fifty thousand US dollars (US$150,000) and 900,000 common shares in the capital of the Company which shares will subject to the usual 4 month restricted period required by the TSX Venture Exchange and applicable securities legislation.

The purchase of the Rights is subject to due diligence by the Company and the completion of formal documentation.

The first step in evaluating this Property the Company intends to undertake an independent NI 43-101 Report which will recommend an initial exploration program.


๐Ÿ‘๏ธ0
Pro-Life Pro-Life 14 years ago
This just keeps stairstepping ahead... amazing.
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 15 years ago
Still holding those tremendous late summer gains...
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 15 years ago
A rockin' good week...
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 15 years ago
Otish Energy Releases NI 43-101 Technical Report on Puruni Gold Project, Guyana

http://finance.yahoo.com/news/Otish-Energy-Releases-NI-ccn-4263905401.html?x=0&.v=1
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 15 years ago
They do not update the website enough...

http://www.otishenergyinc.com/index.html
๐Ÿ‘๏ธ0
Pro-Life Pro-Life 15 years ago
DAILY VIEW:

๐Ÿ‘๏ธ0
Pro-Life Pro-Life 15 years ago
did you see what happened here today?
๐Ÿ‘๏ธ0
profiteer11 profiteer11 15 years ago
http://www.marketwatch.com/story/otish-energy-begins-pre-drilling-exploration-work-on-noyelles-gold-property-abitibi-area-quebec-2010-03-19?reflink=MW_news_stmp
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock